These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 31090036)
1. Outcomes Following Cytoreduction and HIPEC for Pseudomyxoma Peritonei: 10-Year Experience. Narasimhan V; Wilson K; Britto M; Warrier S; Lynch AC; Michael M; Tie J; Akhurst T; Mitchell C; Ramsay R; Heriot A J Gastrointest Surg; 2020 Apr; 24(4):899-906. PubMed ID: 31090036 [TBL] [Abstract][Full Text] [Related]
2. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in pseudomyxoma peritonei of appendiceal origin: result of a single centre study. Di Leo A; Corvasce A; Weindelmayer J; Mason EJ; Casella F; de Manzoni G Updates Surg; 2020 Dec; 72(4):1207-1212. PubMed ID: 32410159 [TBL] [Abstract][Full Text] [Related]
3. Appendiceal pseudomyxoma peritonei: predictors of recurrence and iterative surgery. Kong JC; Flood MP; Guerra GR; Liesegang A; Wong WJ; Mitchell C; Warrier SK; Naidu S; Meade B; Lutton N; Heriot AG Colorectal Dis; 2021 Sep; 23(9):2368-2375. PubMed ID: 34157209 [TBL] [Abstract][Full Text] [Related]
4. [A single-center clinical analysis of 65 cases of pseudomyxoma peritonei from appendiceal origin in the early stage]. Ma RQ; Xia A; Zhai XC; Chen F; Xu HB Zhonghua Zhong Liu Za Zhi; 2019 Sep; 41(9):698-702. PubMed ID: 31550861 [No Abstract] [Full Text] [Related]
5. Perioperative safety after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal origin: Experience on 254 patients from a single center. Li XB; Ma R; Ji ZH; Lin YL; Zhang J; Yang ZR; Chen LF; Yan FC; Li Y Eur J Surg Oncol; 2020 Apr; 46(4 Pt A):600-606. PubMed ID: 31973925 [TBL] [Abstract][Full Text] [Related]
6. Development and Validation of Nomograms to Predict Survival in Patients Undergoing Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei of Appendiceal Origin. Chandrakumaran K; Carr NJ; Mohamed F; Cecil TD; Moran BJ JAMA Surg; 2023 May; 158(5):522-530. PubMed ID: 36920381 [TBL] [Abstract][Full Text] [Related]
7. Twenty-years' experience with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for pseudomyxoma peritonei (PMP). Papantoni E; Ntatsis K; Kyziridis D; Kalakonas A; Hristakis C; Tentes AA J BUON; 2021; 26(4):1647-1652. PubMed ID: 34565031 [TBL] [Abstract][Full Text] [Related]
8. The Role of Hyperthermic Intraperitoneal Chemotherapy in Pseudomyxoma Peritonei After Cytoreductive Surgery. Kusamura S; Barretta F; Yonemura Y; Sugarbaker PH; Moran BJ; Levine EA; Goere D; Baratti D; Nizri E; Morris DL; Glehen O; Sardi A; Barrios P; Quénet F; Villeneuve L; Gómez-Portilla A; de Hingh I; Ceelen W; Pelz JOW; Piso P; González-Moreno S; Van Der Speeten K; Deraco M; JAMA Surg; 2021 Mar; 156(3):e206363. PubMed ID: 33502455 [TBL] [Abstract][Full Text] [Related]
9. Outcomes of cytoreductive surgery and HIPEC for pseudomyxoma peritonei of appendiceal origin from two Indian centers: A preliminary five-year experience. Bhatt A; Sheshadri D; Chandan G; Ramaswamy V; Pandey J; Bhorkar N; Agrawal D; Mehta S J BUON; 2017; 22(1):251-257. PubMed ID: 28365962 [TBL] [Abstract][Full Text] [Related]
10. Hyperthermic intraperitoneal chemotherapy in patients with incomplete cytoreduction for appendiceal pseudomyxoma peritonei: a 10-year treatment experience in China. Wang B; Ma R; Shi G; Fan X; Rao B; Xu H Orphanet J Rare Dis; 2024 Jan; 19(1):8. PubMed ID: 38178189 [TBL] [Abstract][Full Text] [Related]
11. Pleuropulmonary Recurrence Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion for Appendiceal Pseudomyxoma Peritonei. Beane JD; Wilson GC; Sutton JM; Shuai Y; Ramalingam L; Jones HL; Pingpank JF; Holtzman MP; Zureikat AJ; Ahrendt SA; Zeh HJ; Bartlett DL; Choudry HA Ann Surg Oncol; 2019 May; 26(5):1429-1436. PubMed ID: 30623341 [TBL] [Abstract][Full Text] [Related]
12. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of pseudomyxoma peritonei: A single-center experience. Azzam AZ; Alyahya ZA; Wusaibie AAA; Amin TM Indian J Gastroenterol; 2017 Nov; 36(6):452-458. PubMed ID: 29185227 [TBL] [Abstract][Full Text] [Related]
13. Outcomes from cytoreduction and hyperthermic intraperitoneal chemotherapy for appendiceal epithelial neoplasms. Narasimhan V; Pham T; Warrier S; Craig Lynch A; Michael M; Tie J; Ramsay R; Heriot A ANZ J Surg; 2019 Sep; 89(9):1035-1040. PubMed ID: 30685879 [TBL] [Abstract][Full Text] [Related]
14. [Efficacy of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei]. Lei ZY; Ding BH; Wu QY; Luo JL; Li Z; Wang T; Wang YS; Chen YX; Huang LF; He JF; Yang XS; Guan TP; Ruan Q; Wang JH; Tang HS; Wang J; Cui SZ Zhonghua Wei Chang Wai Ke Za Zhi; 2023 Dec; 26(12):1179-1186. PubMed ID: 38110280 [No Abstract] [Full Text] [Related]
15. Validation of the Recent PSOGI Pathological Classification of Pseudomyxoma Peritonei in a Single-Center Series of 265 Patients Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Baratti D; Kusamura S; Milione M; Bruno F; Guaglio M; Deraco M Ann Surg Oncol; 2018 Feb; 25(2):404-413. PubMed ID: 29159742 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of cytoreductive surgery and HIPEC for peritoneal surface malignancies: analysis of 384 consecutive cases. Narasimhan V; Das A; Warrier S; Lynch C; McCormick J; Tie J; Michael M; Ramsay R; Heriot A Langenbecks Arch Surg; 2019 Aug; 404(5):527-539. PubMed ID: 31377856 [TBL] [Abstract][Full Text] [Related]
17. Analysis of causes and prognostic impact of tube occlusion during hyperthermic intraperitoneal chemotherapy for appendiceal pseudomyxoma peritonei. Liu Q; Jiao J; Li C; Chen Y; Wang B; Shi J; Yu G World J Surg Oncol; 2024 May; 22(1):134. PubMed ID: 38769546 [TBL] [Abstract][Full Text] [Related]
18. Long-term survival following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in Waikato, Aotearoa New Zealand: a 12-year experience. Qin RX; Lim JH; Ly J; Fischer J; Smith N; Karalus M; Wu L; van Dalen R; Lolohea S ANZ J Surg; 2024 Apr; 94(4):621-627. PubMed ID: 37994292 [TBL] [Abstract][Full Text] [Related]
19. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei and appendix tumours in elderly patients: Is it justified? López-López V; Cascales-Campos PA; Gil E; Arevalo J; Gonzalez A; Gil J; Muñoz-Casares FC; Melero JT; Barrios P; Morales R; Ramos I; Ortega G; Camps B; González-Bayón L; Bretcha-Boix P; Farré-Alegre J; González-Moreno S; Parrilla P Clin Transl Oncol; 2017 Nov; 19(11):1388-1392. PubMed ID: 28812240 [TBL] [Abstract][Full Text] [Related]
20. Treatment of pseudomyxoma peritonei with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC): a single center experience. Robella M; Vaira M; Marsanic P; Mellano A; Cinquegrana A; Sottile A; De Simone M Minerva Chir; 2013 Dec; 68(6):569-77. PubMed ID: 24193289 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]